IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

VENETIS, KONSTANTINOS
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 5.433
AS - Asia 5.331
NA - Nord America 4.262
SA - Sud America 584
Continente sconosciuto - Info sul continente non disponibili 335
AF - Africa 158
OC - Oceania 46
Totale 16.149
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.990
DE - Germania 2.258
CN - Cina 2.107
IT - Italia 1.325
SG - Singapore 1.214
BD - Bangladesh 418
BR - Brasile 417
HK - Hong Kong 340
GB - Regno Unito 327
IN - India 280
VN - Vietnam 241
RU - Federazione Russa 235
NL - Olanda 227
FR - Francia 215
SE - Svezia 184
ES - Italia 173
CA - Canada 143
JP - Giappone 119
ID - Indonesia 107
TR - Turchia 96
IE - Irlanda 87
FI - Finlandia 80
MX - Messico 77
KR - Corea 76
TW - Taiwan 54
IR - Iran 51
CO - Colombia 48
PL - Polonia 47
AU - Australia 43
AT - Austria 36
PT - Portogallo 33
AR - Argentina 32
EG - Egitto 32
SA - Arabia Saudita 31
CH - Svizzera 30
PH - Filippine 29
BE - Belgio 28
IQ - Iraq 27
ZA - Sudafrica 26
IL - Israele 25
TH - Thailandia 25
PE - Perù 21
PK - Pakistan 19
GH - Ghana 18
RO - Romania 18
GR - Grecia 17
LT - Lituania 17
CI - Costa d'Avorio 16
CL - Cile 16
EC - Ecuador 16
AE - Emirati Arabi Uniti 15
MY - Malesia 14
UA - Ucraina 14
DK - Danimarca 12
KE - Kenya 12
MA - Marocco 12
VE - Venezuela 12
CR - Costa Rica 9
ET - Etiopia 9
NO - Norvegia 9
PY - Paraguay 9
SC - Seychelles 9
UY - Uruguay 9
HN - Honduras 8
RS - Serbia 8
BG - Bulgaria 7
GT - Guatemala 7
HU - Ungheria 7
LU - Lussemburgo 7
TT - Trinidad e Tobago 7
DZ - Algeria 6
NG - Nigeria 6
TN - Tunisia 6
BB - Barbados 5
CZ - Repubblica Ceca 5
JO - Giordania 5
PA - Panama 5
UZ - Uzbekistan 5
AL - Albania 4
BA - Bosnia-Erzegovina 4
BO - Bolivia 4
EE - Estonia 4
GE - Georgia 4
PS - Palestinian Territory 4
SK - Slovacchia (Repubblica Slovacca) 4
SN - Senegal 4
HR - Croazia 3
LB - Libano 3
LK - Sri Lanka 3
MO - Macao, regione amministrativa speciale della Cina 3
NZ - Nuova Zelanda 3
SV - El Salvador 3
AM - Armenia 2
AZ - Azerbaigian 2
BY - Bielorussia 2
CY - Cipro 2
DO - Repubblica Dominicana 2
JM - Giamaica 2
KG - Kirghizistan 2
KW - Kuwait 2
Totale 15.796
Salva come PNG Salva come JPEG
Città #
Frankfurt am Main 2.039
Singapore 660
Dallas 570
Ashburn 558
San Jose 274
Milan 269
Hong Kong 264
Santa Clara 225
Council Bluffs 217
Hefei 203
Beijing 200
Los Angeles 171
Chandler 169
Southend 150
Shanghai 124
New York 108
Guangzhou 101
Dublin 87
Fairfield 84
Rome 80
Bengaluru 79
Ho Chi Minh City 70
Hanoi 69
Jakarta 65
Lauterbourg 65
Istanbul 63
Boardman 62
São Paulo 61
Moscow 59
Buffalo 58
Shenzhen 52
Nanjing 51
Tokyo 51
Zhengzhou 48
Chicago 46
Turin 46
Seattle 43
Helsinki 42
Princeton 42
Munich 41
Wilmington 41
Seoul 40
Naples 37
Toronto 35
Chengdu 33
Houston 32
The Dalles 32
Nuremberg 31
Woodbridge 31
Amsterdam 30
London 30
Ann Arbor 28
Hangzhou 28
Vienna 27
Wuhan 27
Bologna 26
Erechim 26
Hyderabad 26
Berlin 24
Cambridge 24
Shenyang 24
Cangzhou 23
Madrid 23
Des Moines 22
Fuzhou 22
Phoenix 22
Atlanta 21
Florence 21
Lappeenranta 21
Bogotá 20
Gainesville 19
Palermo 19
Paris 19
Changsha 18
Jinan 18
Lima 18
Warsaw 18
Chongqing 17
Orem 17
Tianjin 17
Abidjan 16
Huntley 16
Mexico City 16
San Francisco 16
Bangkok 15
Columbus 15
San Diego 15
Sydney 15
Taipei 15
Washington 15
Accra 14
Athens 14
Barcelona 14
Bergamo 14
Cairo 14
Genoa 14
Manchester 14
Ankara 13
Baltimore 13
Brussels 13
Totale 8.964
Salva come PNG Salva come JPEG
Nome #
CAR-T cell therapy for triple-negative breast cancer and other solid tumors: preclinical and clinical progress 2.717
Quality of Life Interventions in Breast Cancer Survivors: State of the Art in Targeted Rehabilitation Strategies 526
Standardized pathology report for HER2 testing in compliance with 2023 ASCO/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer 369
BREAST CANCER DURING PREGNANCY AS A SPECIAL TYPE OF EARLY-ONSET BREAST CANCER: INSIGHTS INTO THE TUMOR MICROENVIRONMENT AND IMMUNE TRANSCRIPTOME 356
PTEN Expression as a Complementary Biomarker for Mismatch Repair Testing in Breast Cancer 333
Computational pathology to improve biomarker testing in breast cancer: how close are we? 329
Targeting immune-related biological processes in solid tumors : we do need biomarkers 318
Pten alterations and their role in cancer management: Are we making headway on precision medicine? 307
HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer 299
Osteoclast-like stromal giant cells in breast cancer likely belong to the spectrum of immunosuppressive tumor-associated macrophages 268
Immunotherapy in breast cancer patients: A focus on the use of the currently available biomarkers in oncology 268
Integrating Biological Advances Into the Clinical Management of Breast Cancer Related Lymphedema 264
Assessment of estrogen receptor low positive status in breast cancer: Implications for pathologists and oncologists 259
Diagnostic performance of image-guided vacuum-assisted breast biopsy after neoadjuvant therapy for breast cancer: prospective pilot study 255
Body mass index, adiposity and tumour infiltrating lymphocytes as prognostic biomarkers in patients treated with immunotherapy: A multi-parametric analysis 254
Mismatch repair (MMR) and microsatellite instability (MSI) phenotypes across solid tumors: A comprehensive cBioPortal study on prevalence and prognostic impact 252
Breast Cancer with Bone Metastasis: Molecular Insights and Clinical Management 242
Standardized molecular pathology workflow for ctDNA-based ESR1 testing in HR+/HER2- metastatic breast cancer 240
Impact of Rehabilitation on Breast Cancer Related Fatigue : A Pilot Study 238
Early Breast Cancers During Pregnancy Treated With Breast-Conserving Surgery in the First Trimester of Gestation: A Feasibility Study 236
Mismatch repair-deficient hormone receptor-positive breast cancers : Biology and pathological characterization 235
ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial 234
Characterization of the immune microenvironment in malignant pleural mesothelioma reveals prognostic subgroups of patients 229
Efficacy of Antiresorptive Drugs on Bone Mineral Density in Post-Menopausal Women With Early Breast Cancer Receiving Adjuvant Aromatase Inhibitors: A Systematic Review of Randomized Controlled Trials 226
Mismatch Repair Status Characterization in Oncologic Pathology : Taking Stock of the Real-World Possibilities 223
Combined analysis of PTEN, HER2, and hormone receptors status: remodeling breast cancer risk profiling 223
Breast Cancer with Brain Metastasis: Molecular Insights and Clinical Management 221
Tumor-infiltrating lymphocytes (TILs) in paired samples from patients with phenotypic switch from early luminal-like to metastatic triple-negative breast cancer 215
Breast Cancer during Pregnancy as a Special Type of Early-Onset Breast Cancer: Analysis of the Tumor Immune Microenvironment and Risk Profiles 210
Cellular immunotherapy in breast cancer: The quest for consistent biomarkers 203
Genomic and clinical landscape of metastatic hormone receptors-positive breast cancers carrying ESR1 alterations 202
In-house homologous recombination deficiency testing in ovarian cancer: A multi-institutional Italian pilot study 198
Metaplastic breast cancers and triple-negative breast cancers of no special type: are they prognostically different? A systematic review and meta-analysis 187
Low-risk triple-negative breast cancers: Clinico-pathological and molecular features 185
Advancing the PD-L1 CPS test in metastatic TNBC: Insights from pathologists and findings from a nationwide survey 182
Mismatch repair testing in breast cancer: the path to tumor-specific immuno-oncology biomarkers 181
Mismatch Repair System Genomic Scars in Gastroesophageal Cancers: Biology and Clinical Testing 181
ESR1 testing on FFPE samples from metastatic lesions in HR + /HER2- breast cancer after progression on CDK4/6 inhibitor therapy 178
Physical Exercise with or without Whole-Body Vibration in Breast Cancer Patients Suffering from Aromatase Inhibitor—Induced Musculoskeletal Symptoms : A Pilot Randomized Clinical Study 178
Bone Muscle Crosstalk in Spinal Cord Injuries: Pathophysiology and Implications for Patients’ Quality of Life 176
Anti-Claudin Treatments in Gastroesophageal Adenocarcinoma: Mainstream and Upcoming Strategies 175
Immune microenvironment dynamics in breast cancer during pregnancy: impact of gestational age on tumor-infiltrating lymphocytes and prognosis 172
Letter to the editor regarding the article “pregnancy-associated breast cancer: a multicenter study comparing clinicopathological factors, diagnosis, and treatment outcomes with non-pregnant patients” 166
HER2 in Metastatic Colorectal Cancer: Pathology, Somatic Alterations, and Perspectives for Novel Therapeutic Schemes 165
Immune Biomarkers in Triple-Negative Breast Cancer: Improving the Predictivity of Current Testing Methods 164
PD-L1 testing in metastatic triple-negative breast cancer: Interobserver and interplatform reproducibility of CE-IVD assays for CPS and IC scores 161
Trop-2 as an Actionable Biomarker in Breast Cancer 157
The molecular landscape of breast mucoepidermoid carcinoma 154
Analytical Performance of Next-Generation Sequencing and RT-PCR on Formalin-Fixed Paraffin-Embedded Tumor Tissues for PIK3CA Testing in HR+/HER2− Breast Cancer 149
Circulating tumour DNA testing in metastatic breast cancer: Integration with tissue testing 146
Clinicopathological features and survival outcomes of luminal-like breast tumors with estrogen receptor loss at metastatic recurrence: A case-control study 143
Spatially Resolved Molecular Approaches for the Characterisation of Non-Invasive Follicular Tumours with Papillary-like Features (NIFTPs) 143
Inter-Assay Variability of TROP2 Immunohistochemistry in Triple-Negative Breast Cancer 142
The Evolving Role of Genomic Testing in Early Breast Cancer: Implications for Diagnosis, Prognosis, and Therapy 141
Pathological identification of HER2-low breast cancer: Tips, tricks, and troubleshooting for the optimal test 139
PIK3CA testing in hormone receptor-positive/HER2-negative metastatic breast cancer: real-world data from Italian molecular pathology laboratories 135
Early Breast Cancer Risk Assessment: Integrating Histopathology with Artificial Intelligence 135
Exercise therapy to reduce breast cancer fatigue: Results from the EXPECT study 124
Investigating the Pathogenicity of Uncommon KRAS Mutations and Their Association with Clinicopathologic Characteristics in Patients with Colorectal Cancer 117
Biomarkers for precision immunotherapy in the metastatic setting : hope or reality? 112
ctDNA analysis in the personalized clinical management of gastroesophageal adenocarcinoma: turning hope into reality 109
Malignancies in Patients with Celiac Disease: Diagnostic Challenges and Molecular Advances 106
ESR1 mutations in HR+/HER2-metastatic breast cancer: Enhancing the accuracy of ctDNA testing 92
Understanding the biology of volumetric muscle loss for an individualized exercise rehabilitation approach in breast cancer patients 92
Non-Small Cell Lung Cancer Testing on Reference Specimens: An Italian Multicenter Experience 91
Think “HER2” different: integrative diagnostic approaches for HER2-low breast cancer 85
Improving HER2 testing reproducibility in HER2-low breast cancer 58
Commentary: Mismatch Repair Deficiency and Microsatellite Instability in Triple-Negative Breast Cancer: A Retrospective Study of 440 Patients 55
PIK3CA testing in HR+/HER2- metastatic breast cancer: assessing pathology laboratories capacity and needs 24
Artificial Intelligence in Thyroid Cytopathology: Diagnostic and Technical Insights 22
Next-generation sequencing methodologies to identify patients for targeted therapy: focus on HR+/HER2- metastatic breast cancer 20
Computational pathology in breast cancer: optimizing molecular prediction through task-oriented AI models 20
Multi-omics integrative modelling for stereotactic body radiotherapy in early-stage non-small cell lung cancer: clinical trial protocol of the MONDRIAN study 16
Unfavorable carcinoma of unknown primary with a gastrointestinal profile: a retrospective study 14
Corrigendum to: "Body mass index, adiposity and tumour infiltrating lymphocytes as prognostic biomarkers in patients treated with immunotherapy: A multi-parametric analysis" [Eur J Cancer 145 (2021) 197-209] 8
Totale 16.149
Salva come PNG Salva come JPEG
Categoria #
all - tutte 39.368
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 39.368
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022457 0 28 21 33 39 39 39 33 90 43 21 71
2022/2023671 62 57 47 69 46 110 22 44 80 6 47 81
2023/20243.037 112 95 123 147 248 211 413 379 228 331 381 369
2024/20254.234 375 464 399 411 266 253 164 352 296 372 321 561
2025/20266.578 656 840 737 526 436 335 591 294 525 390 677 571
2026/2027590 339 251 0 0 0 0 0 0 0 0 0 0
Totale 16.149